Tissue-targeted nucleic acid delivery
Getting mRNA, DNA or editor payloads into a chosen tissue outside the liver at therapeutic dose, with redosing possible. (CNS delivery is covered separately.)
State of the art
Polymer-lipid nanoparticles delivering Dsup mRNA produced protective protein expression confined to mouse oral and rectal tissue (Nature Biomedical Engineering, 2025); approved LNP and AAV products target liver, eye and muscle only.
- Systemic LNPs partition to liver and spleen; tropism for kidney, bone marrow and solid tumors is weak
- Anti-AAV immunity excludes many patients and blocks redosing
- Payload size caps (about 4.7 kb for AAV) exclude large multi-gene constructs
Who’s working on it
- Daniel SiegwartResearcherUT Southwestern Medical Center
Invented selective organ targeting lipid nanoparticles that redirect mRNA to lung and spleen, and in 2025 traced the effect to protein-corona composition
- Dyno TherapeuticsStartup
Designs AAV capsids with machine learning; licensed a CNS capsid to Roche in January 2025 and had a skeletal-muscle capsid optioned by Astellas
- Capsida BiotherapeuticsStartup
Engineers tissue-selective capsids paired with its own manufacturing, aimed specifically at targets outside the liver
- Tessera TherapeuticsStartup
Its proprietary lipid nanoparticles delivered Gene Writers to haematopoietic stem cells and T cells in primates with editing durable to about 15 months (2025)
- Giovanni TraversoResearcherMassachusetts Institute of Technology
Produced tissue-confined mRNA expression in mouse oral and rectal mucosa using polymer-lipid nanoparticles (Nature Biomedical Engineering, 2025)
- Alnylam PharmaceuticalsCompany
Its approved GalNAc-conjugated siRNA drugs define what reliable delivery looks like and also define the ceiling, since they reach only hepatocytes
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Directed-evolution and designed-capsid campaigns validated in nonhuman primates for three non-liver target tissues | $$$ $100M – $1B |
| engineering | Manufacturing and release-assay capacity for clinical-grade vectors at 1e16 genome doses | $$$ $100M – $1B |